SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
3 references·1 citing·20 second hop
Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China (2021)Cost-Effectiveness Analysis of Camrelizum…Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy (2014)Cost-effectiveness analysis o…Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial (2013)Survival Modeling for the Est…Development of WHO guidelines on generalized cost-effectiveness analysis (2000)Development of WHO guidelines…Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis (2022)Pembrolizumab Plus Chemothera…Bulletin of the World Health Organization (1955)Cost-Effectiveness in Health and Medicine (1996)Generalized cost-effectiveness analysis for national-level priority-setting in the health sector (2003)Generalisability in economic evaluation studies in healthcare: a review and case studies (2004)Methods for the Economic Evaluation of Health Care Programmes (2005)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Decision Modelling For Health Economic Evaluation (2006)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data (2013)Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆ (2017)Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer (2018)Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives (2020)Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)China's health system and its reform: a review of recent studies (2009)Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China (2016)Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China (2018)Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma (2020)One Thousand Health-Related Quality-of-Life Estimates (2000)Health state utilities for non small cell lung cancer (2008)The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment (2018)
this work references cited by second hop

References

  • 2000Development of WHO guidelines on generalized cost-effectiveness analysis578 cited
  • 2013Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial136 cited
  • 2014Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy72 cited

Cited by

  • 2022Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis50 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work